Insurers still overlook breast cancer screening
This year's annual report from the National Committee for Quality Assurance showed a mixed bag of good and bad news, reported Managed Care (11/2005). Of the 289 commercial health plans that reported data to the NCQA, the average performance showed improvements in 18 of 22 clinical measures.
This year's annual report from the National Committee for Quality Assurance showed a mixed bag of good and bad news, reported Managed Care (11/2005). Of the 289 commercial health plans that reported data to the NCQA, the average performance showed improvements in 18 of 22 clinical measures. First the bad news: The average performance of the health plans worsened with respect to breast cancer screening. On the other hand, the clinical measures that did show improvement included beta-blocker treatment after a heart attack, comprehensive diabetes care, cholesterol management control, high blood pressure control, and childhood immunization status.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
